Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.

Nevertheless, patients with high‐risk cytogenetics showed a trend toward lower 3‐year PFS than those without (77.8% vs. 89.4%, p = 0.051), and ultra‐high‐risk cytogenetics (≥2 high‐risk cytogenetics) had an even worse prognosis, with 61.2% 3‐year PFS.

also in 53,322 other papers